menu
    • menu
    [{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zogenix \/ Not Applicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ Not Applicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zogenix \/ Not Applicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"Sigma opioid receptor","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ Not Applicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ Not Applicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Nippon Shinyaku","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Zogenix","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ PPD","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ PPD"},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zogenix \/ Not Applicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ Not Applicable"},{"orgOrder":0,"company":"Zogenix","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","graph1":"Neurology","graph2":"Approved","graph3":"Zogenix","amount2":1.8999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":1.8999999999999999,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ UCB","highestDevelopmentStatusID":"12","companyTruncated":"Zogenix \/ UCB"},{"orgOrder":0,"company":"Zogenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Zogenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Zogenix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zogenix \/ Not Applicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2B receptor","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"5-HT2 receptor","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fenfluramine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for (+-)-Fenfluramine

    Menu

    (+-)-Fenfluramine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            UCB Pharma S.A

                            Belgium arrow
                            CPhI India 2024
                            Not Confirmed

                            UCB Pharma S.A

                            Belgium arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FINTEPLA (fenfluramine) Oral Solution Recommended for Approval in The EU For Adjunctive Treatment of Seizures ...

                            Details : FINTEPLA (fenfluramine) is a serotonin releasing agent, and thereby stimulates multiple 5-HT receptor sub-types through the release of serotonin. Fenfluramine may reduce seizures by acting as an agonist at specific serotonin receptors in the brain.

                            Brand Name : Fintepla

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 19, 2022

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            UCB Pharma S.A

                            Belgium arrow
                            CPhI India 2024
                            Not Confirmed

                            UCB Pharma S.A

                            Belgium arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FINTEPLA (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet Syndrome

                            Details : Approval supported by clinical trial data that showed when added to existing treatment regimens, Fintepla (fenfluramine) significantly reduced monthly convulsive seizure frequency compared to placebo.

                            Brand Name : Fintepla

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 27, 2022

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            UCB Pharma S.A

                            Belgium arrow
                            CPhI India 2024
                            Not Confirmed

                            UCB Pharma S.A

                            Belgium arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA[®]▼(fenfluramine) Ora...

                            Details : Primary endpoint was met demonstrating that Fintepla (fenfluramine), as adjunctive treatment, is effective in significantly reducing the frequency of drop seizures in LGS patients compared to placebo.

                            Brand Name : Fintepla

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 02, 2022

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Zogenix

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Zogenix

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : UCB Pharma S.A

                            Deal Size : $1,900.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            UCB Completes Acquisition of Zogenix, Inc.

                            Details : FINTEPLA® (fenfluramine) oral solution is a prescription medication approved in the U.S. and Europe, and under regulatory review in Japan, for the treatment of seizures associated with Dravet syndrome in patients two years of age and older.

                            Brand Name : Fintepla

                            Molecule Type : Small molecule

                            Upfront Cash : $1,900.0 million

                            March 07, 2022

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : UCB Pharma S.A

                            Deal Size : $1,900.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Zogenix

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Zogenix

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2...

                            Details : FINTEPLA (fenfluramine) is approved by the FDA and European Commission for the treatment of seizures associated with Dravet syndrome and is in development in Japan for the treatment of seizures associated with Dravet syndrome.

                            Brand Name : Fintepla

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 04, 2022

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Zogenix

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Zogenix

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zogenix Submits New Drug Application for FINTEPLA® (Fenfluramine) in Japan for the Treatment of Epileptic Sei...

                            Details : The submission is based on the results of Phase 3, which met its primary objective in demonstrating that patients in the FINTEPLA (Fenfluramine) achieved a 64.8% greater reduction in mean monthly convulsive seizures compared to the placebo group.

                            Brand Name : Fintepla

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 21, 2021

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Zogenix

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Zogenix

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New FINTEPLA® (Fenfluramine) Data Show Long-Term Seizure Frequency Reductions in Patients with Lennox-Gastaut...

                            Details : In the long-term trial, FINTEPLA was generally well tolerated with no observed valvular heart disease or pulmonary hypertension.

                            Brand Name : Fintepla

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 30, 2021

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Zogenix

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Zogenix

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : PPD

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zogenix Submits Supplemental New Drug Application for FINTEPLA® (Fenfluramine) for the Treatment of Seizures ...

                            Details : sNDA is supported by Phase 3 Study 1601 for FINTEPLA® (fenfluramine) for treatment of seizures associated with Lennox-Gastaut Syndrome to FDA. FINTEPLA is approved by the FDA and European Commission for treatment of seizures associated with Dravet syndr...

                            Brand Name : Fintepla

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 28, 2021

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : PPD

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Zogenix

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Zogenix

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Nippon Shinyaku

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zogenix Receives Orphan Drug Designation for FINTEPLA® (Fenfluramine) in Japan

                            Details : Zogenix plans to submit a new drug application (J-NDA) for FINTEPLA in Japan for the treatment of seizures associated with Dravet syndrome by year end.

                            Brand Name : Fintepla

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 26, 2021

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Nippon Shinyaku

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Zogenix

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Zogenix

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zogenix Product FINTEPLA® (Fenfluramine) Recognized for Setting a New Standard for Dravet Syndrome Treatment ...

                            Details : Across studies, FINTEPLA has been generally well-tolerated, with no observed cases of pulmonary arterial hypertension (PAH) or valvular heart disease (VHD). The most common adverse events were reported as decreased appetite, fatigue, diarrhea, and pyrexi...

                            Brand Name : Fintepla

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 21, 2021

                            Lead Product(s) : Fenfluramine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth